Centre National De La Recherche Scientifique

Biomerieux, Inc.

Universite Claude Bernard – Lyon1

Hospices Civils De Lyon

Centre Hospitalier Universitaire De Nantes

Agence Francaise De Securite Sanitaire Des Aliments

Agence Francaise De Securite Sanitaire Des Aliments-afssa

Universite Claude Bernard Lyon and Biomerieux

Marilyne Dupin

Herve Perron

Anthony William Coleman

Eric Da Silva

Ambroise Martin

Aly Moussa

Edwige Leclere

Guillaume Monneret

Tanguy Fortin

Fabienne Venet

Alexandre Pachot

Karim Asehnoune

Sylvie Pons

Frederic Ronzon

Patrick Shahgaldian

Antoine Roquilly

Aurélie Gouel-Cheron

Audrey Larue-Triolet

Anna Benscik-Reynier

Adina Nicoleta Lazar

Bernard Allaouchiche

Frédéric Ronzon

Hervé Perron

A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a &#x394; value; and comparing the &#x394; value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Prediction of the risk of developing a disseminated infection for patients admitted to an intensive care unit

The invention relates to a method for detecting PrP in a biological human or animal sample that may contain PrP. The inventive method is characterised in that it uses a molecule containing at least one positive charge and/or at least one osidic bond and a ligand other than a proteinic ligand selected from macrocyclic ligands and glycosaminoglycanes.

Method for detecting PrP using at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand

A process for detecting the forms of the prion pathogens responsible for subacute, transmissible, spongiform encephalopathies, including a macrocyclic adjuvant ligand (AML), free or bound to a support, that is added to a biological sample capable of containing PrP, the resulting suspension then being reacted with an anti-PrPantibody, and the presence of PrP is then detected.

Process for detecting PrP using a macrocyclic adjuvant ligand

Growing community of inventors

Vaugneray, France

Marilyne Dupin